Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
7 hedge funds and large institutions have $3.18M invested in Proshares UltraPro NASDAQ Biotechnology in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
29% more capital invested
Capital invested by funds: $2.47M → $3.18M (+$715K)
24% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $834K
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$808K |
| 2 |
VF
Virtu Financial
New York
|
+$755K |
| 3 |
Jane Street
New York
|
+$330K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$253K |
| 5 |
Morgan Stanley
New York
|
+$15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$810K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$126K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$58.1K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$5K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$2K |
UBIO Hedge Fund Activity: Q2 2016 in Review
7 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q2 2016, worth a combined $3.18M — up 29% from $2.47M a quarter earlier.
Fund positioning in UBIO was balanced in Q2 2016: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $808K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $810K sold.
- 7 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $3.18M of Proshares UltraPro NASDAQ Biotechnology stock for Q2 2016, up 29% quarter-over-quarter.
- 3 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q2 2016 and 3 closed out, a net change of 0 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q2 2016 was Tower Research Capital (TRC), an estimated $808K added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q2 2016 was Susquehanna International Group, an estimated $810K sold.
Based on aggregated 13F filings for Q2 2016.